# Paper
[Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102646/)

## Paper Code

## Insights
1. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir are potentially potent drugs against SARS-CoV-2 since they tightly bind to its RdRp (RNA dependent RNA polymerase)


## Methods
1. [NCBI GeneBank Sars-CoV-2 Orf1ab](https://www.ncbi.nlm.nih.gov/nuccore/NC_045512.2?report=genbank&from=266&to=21555)
1. [BLAST Sars-CoV-2 Orf1ab](https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Nucleotides&PROGRAM=blastn&QUERY=NC_045512.2&DATABASE=nr&MEGABLAST=on&BLAST_PROGRAMS=megaBlast&LINK_LOC=nuccore&PAGE_TYPE=BlastSearch&QUERY_FROM=266&QUERY_TO=21555)
    - For Database choose PDB nucleotide database (pdb) 
1. Get most similar homologous target, in this case the Sars-CoV-1 6NUR protein (nsp12).
1. [6NUR RCSB](https://www.rcsb.org/structure/6nur)

#### HLA (Human Leukocyte Antigen) Population Allele Analysis
#### Population Coverage Pickle File
#### Data Format

## What I Learned